This Is MS Multiple Sclerosis Knowledge & Support Community

Posted: **Thu Jun 29, 2017 4:28 am**

Rapid and robust B-cell depletion reported in preliminary phase II study of ublituximab

Relapsing remitting multiple sclerosis (RRMS) patients treated with ublituximab (TG-1101) have exhibited a median B-cell depletion of 99% at week four of an ongoing five month study, conducted by TG Therapeutics, Inc...Read more - http://www.ms-uk.org/rapid-and-robust-b ... mab-290617

Posted: **Sun Jul 02, 2017 10:15 pm**

Thanks again. The news page of MS-UK is currently the best source of information in the web.

Posted: **Sun Jul 02, 2017 11:21 pm**

Thank you for this feedback, means a lot

This Is MS Multiple Sclerosis Knowledge & Support Community

Results of preliminary phase II study of ublituximab in RRMS

Results of preliminary phase II study of ublituximab in RRMS

Re: Results of preliminary phase II study of ublituximab in

Re: Results of preliminary phase II study of ublituximab in